Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | JUN | P05412 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16061960 | 0.81 | JUN (0.54) | KDM4EJUNNFKB1NFKB2RELA | |
| SCHEMBL1366624 | 0.80 | JUN (0.42) | KDM4EJUNNFKB1NFKB2RELA | |
| SCHEMBL7336729 | 0.76 | CYP1A2 (0.55) | KDM4ELMNACHEK1GSK3BPLK4 | |
| SCHEMBL9853425 | 0.75 | KDM4E (0.38) | KDM4EJUNNFKB1NFKB2RELA | |
| SCHEMBL9853428 | 0.74 | KDM4E (0.37) | KDM4EJUNNFKB1NFKB2RELA | |
| SCHEMBL17059744 | 0.73 | LMNA (0.46) | KDM4EJUNNFKB1NFKB2RELA | |
| SCHEMBL1366565 | 0.73 | LMNA (0.58) | LMNACHEK1MAPTTP53PDGFRA | |
| SCHEMBL380110 | 0.72 | ALOX5 (0.61) | KDM4ELMNAGSK3BMAPTTP53 | |
| SCHEMBL10391158 | 0.71 | FER (0.55) | CHEK1GSK3BPLK4AURKACHEK2 | |
| SCHEMBL172370 | 0.70 | LMNA (0.58) | LMNACHEK1MAPTTP53PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| WO-2007067875-A2 | PYRIDINYL SULFONAMIDE MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMTED (GB) | 2007-06-14 | — | — | WO | disclosed |
| US-5547951-A | ENZYME INHIBITORS; AIDS | BOEHRINGER INGELHEIM PHARAMCEUTICALS, INC. (US) | 1996-08-20 | — | — | US | disclosed |
| EP-0417534-A1 | Pyrido[2,3-b][1,4]benzoxazepin (and thiazepin)-6(5H)-ones and thiones and their use in the prevention or treatment of AIDS | Boehringer Ingelheim Pharmaceuticals Inc. (US) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | CCR2, CCR1, CCRL2 | KDM4E 4528/4885JUN 4057/4885NFKB1 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.